200
Participants
Start Date
November 30, 2007
Primary Completion Date
July 31, 2012
Study Completion Date
August 31, 2012
Afamelanotide (CUV1647)
16 mg subcutaneous implant administered every 60 days
Placebo
Placebo subcutaneous implant administered every 60 days
The Princess Alexandra Hospital, Brisbane
The Queen Elizabeth Hospital, Adelaide
The Royal Melbourne Hospital, Melbourne
Hospital Erasme, Brussels
Gent University Hospital, Ghent
University Hospital, Besançon
Charité Univeritätsklinikum, Berlin
Kiel University Hospital, Kiel
Ospedali Riuniti di Bergamo, Bergamo
University of Padua, Padua
Karolinska University Hospital, Stockholm
Universitätsspital Zürich, Zurich
Lead Sponsor
Clinuvel Pharmaceuticals Limited
INDUSTRY